newsfilter
← Latest News
GlobeNewswire·

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents